Drugs Xagena
Empagliflozin is an oral selective SGLT-2 inhibitor that acts by blocking the reabsorption of glucose in the proximal tubules in the kidneys, and promotes excretion of excess glucose in the urine. ...
The European Commission has granted marketing authorisation for Empagliflozin ( Jardiance ), a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor. Empagliflozin has been approved for the treatment of ...
The FDA ( Food and Drug Administration ) Advisory Committee has voted 12-11 that substantial evidence exists to establish that Jardiance ( Empagliflozin ) reduces cardiovascular death in adults with t ...
The FDA ( Food and Drug Administration ) has approved a new indication for Jardiance ( Empagliflozin ) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established ...
The European Commission ( EC ) has granted marketing authorization for Jardiance ( Empagliflozin ), an oral, once-daily, highly selective sodium-glucose cotransporter 2 ( SGLT2 ), as a treatment for a ...
